Company intelligence / Profile preview
Foghorn Therapeutics
Cambridge, Massachusetts, United Statesfoghorntx.com ↗
- Ownership
- Public · FHTX
- Employees
- ~100
- Development stage
- Other
01
Overview
Foghorn Therapeutics has advanced its lead candidate, the oral selective SMARCA2 inhibitor FHD‑909, into a Phase 1 trial for patients with SMARCA4-mutated cancers—primarily non-small cell lung cancer. Early clinical responses have been observed in other programs such as the AML study of FHD‑286 but did not meet internal efficacy thresholds to continue independently. The company’s pipeline includes several preclinical assets targeting chromatin regulatory proteins such as ARID1B, CBP, and EP300. Preclinical data support further exploration of these agents both as monotherapies and in combination regimens. The company maintains a strong cash position supporting operations into at least late 2026 or early 2027.
- Therapeutic areas
- Oncology
- Modalities
- Small molecules (inhibitors and degraders)Precision therapeutics targeting gene expression/chromatin regulatory system
- Industry
- Biotech
02
Drug pipeline
8 assets7 more assets in the full pipeline.
03
Partnerships
Eli Lilly/Loxo@Lilly – strategic collaboration on oncology medicines including co-development/co-commercialization agreement for selective SMARCA2 program plus additional discovery programs from Gene Traffic Control® platform.
04
Financials
- Market cap
- $113.1M
- Total revenue
- $30.9M
- Enterprise value
- $-11.4M
Beyond the preview
Go deeper on Foghorn Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Foghorn Therapeutics.